Rate My Professor Erin Harvey

Dr Harvey has authored numerous publications in leading respiratory medicine journals. Key works include 'Unlocking Asthma Remission: Key Insights From an Expert Roundtable Discussion' (Respirology, 2025, with Thomas D et al.), 'Mepolizumab treatment and reduced oral corticosteroid exposure improves symptoms of depression and anxiety in severe eosinophilic asthma: data from the Australian Mepolizumab Registry' (Respiratory Medicine, 2025, with Harvey ES et al.), 'Distinct trajectories of treatment response to mepolizumab toward remission in patients with severe eosinophilic asthma' (European Respiratory Journal, 2025, with Hamada Y et al.), 'Early Treatment Response to Mepolizumab Predicts Clinical Remission in Severe Eosinophilic Asthma' (Journal of Allergy and Clinical Immunology in Practice, 2025, with Hamada Y et al.), and 'Impact of clinical remission on quality of life in severe eosinophilic asthma treated with mepolizumab' (Annals of Allergy Asthma and Immunology, 2025, with Hamada Y et al.). Other significant publications encompass biologics-induced remission in severe asthma (ALLERGY, 2024), comorbidities modifying phenotype and treatment effectiveness to mepolizumab (Journal of Allergy and Clinical Immunology in Practice, 2023), impact of landscape fire smoke exposure on asthma patients (Journal of Allergy and Clinical Immunology in Practice, 2023), asthma registries as tools for knowledge generation (Respirology, 2023), prolonged bushfire smoke exposure in severe asthma (International Journal of Environmental Research and Public Health, 2022), mepolizumab and oral corticosteroid stewardship (Journal of Allergy and Clinical Immunology in Practice, 2021), and characterization of severe asthma worldwide from the International Severe Asthma Registry (CHEST, 2020). Her research highlights treatment trajectories, super-responders, environmental impacts, and improvements in patient outcomes.